HYALGAN PREFILLED SYRINGE

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

HYALURONATE SODIUM

Commercializzato da:

Fidia Farmaceutici S.p.A.

Codice ATC:

M09AX01

INN (Nome Internazionale):

HYALURONATE SODIUM

Dosaggio:

20mg/2ml Mg/Ml

Forma farmaceutica:

Solution for Injection

Tipo di ricetta:

Product subject to prescription which may not be renewed (A)

Area terapeutica:

hyaluronic acid

Stato dell'autorizzazione:

Marketed

Data dell'autorizzazione:

1999-04-01

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Hyalgan solution for intra-articular injection, 20 mg/2 ml, prefilled
syringe.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each pre-filled syringe contains 20 mg/2 ml of Sodium hyaluronate.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Solution for intra-articular injection.
Clear, viscous solution
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the sustained relief of pain in osteoarthritis of the knee.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
ADULTS (INCLUDING THE ELDERLY)
The contents of one pre-filled syringe (20 mg/2mL) to be injected into
the affected joint once a week to a total of five
injections, using a standard technique. No adjustment of dose is
required in elderly patients.
This can be repeated at not less than 6 monthly intervals.
CHILDREN
At present there is not enough evidence to recommend a dosage regimen
for use in children.
Intra-articular injection of Hyalgan should be made using precise,
anatomical localisation into the joint cavity of the
knee to be treated. The injection site in the knee is determined by
that location which is easier to reach. Usually a lateral
approach can be followed, but in some cases a medial approach is
preferable. Strict aseptic precautions should be
observed during the administration in order to avoid the possibility
of developing infections in the injection site. The
solution in the pre-filled syringe is ready for use and requires only
a sterile disposable needle. To ensure sterility the
injection site must be carefully cleansed with antiseptic. Care should
be taken to expel any trapped air bubbles from the
syringe containing Hyalgan prior to administration.
Joint effusion, if present, should be aspirated by arthrocentesis
prior to injection of Hyalgan.
The arthrocentesis should be made using a 20 gauge needle and the
joint should be aspirated to almost dryness, but not
to degree that would compromise the accuracy of the subsequent Hyalgan
injection. An appropriate exami